

**FDA-EX-T05**  
**Duration of Treatment Exposure**  
**Safety Population**

Parameter	Xanomeline Low Dose (N=XX)	Xanomeline High Dose (N=XX)	Placebo (N=XX)	Risk Difference (%) (95% CI) [1]	Risk Difference (%) (95% CI) [2]
<b>Duration of treatment, days [3]</b>					
Mean (SD)	XX.X (XX.XX)	XX.X (XX.XX)	XX.X (XX.XX)		
Median	XX.X	XX.X	XX.X		
Min, Max	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X		
Q1, Q3	XX.X, XX.X	XX.X, XX.X	XX.X, XX.X		
<b>Subjects treated, by duration, n (%)</b>					
Any duration (at least 1 dose)	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
<1 month	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
>=1 month	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
>=3 month	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
>=6 month	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
>=12 month	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)

Source: ADSL; Program name: fda-ex-t05.sas;

Abbreviations: CI, confidence interval; N, number of subjects in treatment arm; n, number of subjects with given treatment duration; NE, non evaluable; SD, standard deviation; Q1, 1st quartile; Q3, 3rd quartile.

[1] Difference is shown between Xanomeline Low Dose vs. Placebo.

[2] Difference is shown between Xanomeline High Dose vs. Placebo.

[3] Duration of treatment = Number of days from first dose to last dose of study drug for each subject calculated as (treatment end date - treatment start date) + 1.